These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 8097693)

  • 1. Disposition of zatosetron, a serotonin (5-HT3) receptor antagonist, in humans.
    Franz PM; Mattiuz EL; Hatcher BL; DeSante KA; Breau AP; Occolowitz JL; Dorman DE; Schmid CR; Goldberg MJ; Rubin A
    Drug Metab Dispos; 1993; 21(2):249-54. PubMed ID: 8097693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of zatosetron on ipecac-induced emesis in dogs and healthy men.
    Schwartz SM; Goldberg MJ; Gidda JS; Cerimele BJ
    J Clin Pharmacol; 1994 Mar; 34(3):250-4. PubMed ID: 7517409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic toxicity of zatosetron, a 5-HT3 receptor antagonist, in rhesus monkeys.
    Bendele A; Means J; Shoufler J; Schmalz C; Hanasono G; Symanowski J; Adams E
    Drug Chem Toxicol; 1995 Feb; 18(1):61-82. PubMed ID: 7768200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic toxicity, metabolism, and pharmacokinetics of the 5-HT3 receptor antagonist zatosetron (LY277359) in Fischer 344 rats.
    Bendele AM; Buenger DA; McGrath JP; Schmalz CA; Hanasono GK
    Fundam Appl Toxicol; 1994 May; 22(4):494-504. PubMed ID: 8056197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zatosetron, a 5-HT3 receptor antagonist in a multicenter trial for acute migraine.
    Chappell AS; Bay JM; Botzum GD; Cohen ML
    Neuropharmacology; 1994; 33(3-4):509-13. PubMed ID: 7984290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro metabolism of zatosetron. Interspecies comparison and role of CYP 3A.
    Ring BJ; Parli CJ; George MC; Wrighton SA
    Drug Metab Dispos; 1994; 22(3):352-7. PubMed ID: 8070310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism, pharmacokinetics, and excretion of a nonpeptidic substance P receptor antagonist, ezlopitant, in normal healthy male volunteers: characterization of polar metabolites by chemical derivatization with dansyl chloride.
    Prakash C; O'Donnell J; Khojasteh-Bakht SC
    Drug Metab Dispos; 2007 Jul; 35(7):1071-80. PubMed ID: 17431029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonism of serotonin3 (5-HT3) receptors within the blood-brain barrier prevents cisplatin-induced emesis in dogs.
    Gidda JS; Evans DC; Cohen ML; Wong DT; Robertson DW; Parli CJ
    J Pharmacol Exp Ther; 1995 May; 273(2):695-701. PubMed ID: 7752072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys.
    Mattiuz E; Franklin R; Gillespie T; Murphy A; Bernstein J; Chiu A; Hotten T; Kassahun K
    Drug Metab Dispos; 1997 May; 25(5):573-83. PubMed ID: 9152596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects.
    Miao Z; Nucci G; Amin N; Sharma R; Mascitti V; Tugnait M; Vaz AD; Callegari E; Kalgutkar AS
    Drug Metab Dispos; 2013 Feb; 41(2):445-56. PubMed ID: 23169609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans.
    Renzulli C; Nash M; Wright M; Thomas S; Zamuner S; Pellegatti M; Bettica P; Boyle G
    Drug Metab Dispos; 2011 Feb; 39(2):215-27. PubMed ID: 21045199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships.
    Robertson DW; Lacefield WB; Bloomquist W; Pfeifer W; Simon RL; Cohen ML
    J Med Chem; 1992 Jan; 35(2):310-9. PubMed ID: 1732548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.
    Christopher LJ; Hong H; Vakkalagadda BJ; Clemens PL; Su H; Roongta V; Allentoff A; Sun H; Heller K; Harbison CT; Iyer RA; Humphreys WG; Wong T; Zhang S
    Drug Metab Dispos; 2010 Nov; 38(11):2049-59. PubMed ID: 20668249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism and disposition of a potent and selective GABA-Aalpha2/3 receptor agonist in healthy male volunteers.
    Polsky-Fisher SL; Vickers S; Cui D; Subramanian R; Arison BH; Agrawal NG; Goel TV; Vessey LK; Murphy MG; Lasseter KC; Simpson RC; Vega JM; Rodrigues AD
    Drug Metab Dispos; 2006 Jun; 34(6):1004-11. PubMed ID: 16510541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disposition and metabolism of radiolabeled casopitant in humans.
    Pellegatti M; Bordini E; Fizzotti P; Roberts A; Johnson BM
    Drug Metab Dispos; 2009 Aug; 37(8):1635-45. PubMed ID: 19420128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man.
    Mizojiri K; Okabe H; Sugeno K; Misaki A; Ito M; Kominami G; Esumi Y; Takaichi M; Harada T; Seki H; Inaba A
    Arzneimittelforschung; 1997 Mar; 47(3):259-69. PubMed ID: 9105544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disposition in humans of racemic picenadol, an opioid analgesic.
    Franz PM; Anliker SL; Callaghan JT; DeSante KA; Dhahir PH; Nelson RL; Rubin A
    Drug Metab Dispos; 1990; 18(6):968-73. PubMed ID: 1981546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
    Prakash C; Kamel A; Gummerus J; Wilner K
    Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 5-HT3 receptor antagonist zatosetron decreases the number of spontaneously active A10 dopamine neurons.
    Rasmussen K; Stockton ME; Czachura JF
    Eur J Pharmacol; 1991 Nov; 205(1):113-6. PubMed ID: 1811993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites.
    Prakash C; Cui D
    Drug Metab Dispos; 1997 Dec; 25(12):1395-406. PubMed ID: 9394030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.